{
    "hands_on_practices": [
        {
            "introduction": "Effective clinical practice involves constantly updating our diagnostic certainty in light of new evidence. This exercise puts this principle into practice by using Bayes' theorem to calculate how a positive PCR result transforms an initial suspicion of sporotrichosis into a high-confidence diagnosis. Mastering this quantitative approach is essential for evidence-based decision-making in dermatology .",
            "id": "4492682",
            "problem": "A clinician in dermatology and venereology evaluates a patient with suspected sporotrichosis. Before testing, the clinician estimates the pretest probability of sporotrichosis to be $0.20$. The patient undergoes a polymerase chain reaction (PCR) assay for Sporothrix species, which has sensitivity $0.90$ and specificity $0.98$. Using Bayes’ theorem and the core definitions of sensitivity and specificity as conditional probabilities, derive from first principles an expression for the post-test probability of sporotrichosis given a positive PCR result, and compute its numerical value. Express the final probability as a decimal without a percent sign and round your answer to four significant figures. Then, based on your computed result, provide a brief interpretation for clinical decision-making in suspected sporotrichosis.",
            "solution": "The problem requires the derivation and calculation of the post-test probability of a disease (sporotrichosis) given a positive test result, based on the provided pretest probability, test sensitivity, and specificity. This is a direct application of Bayes' theorem in a clinical diagnostic context. We will first formalize the problem using standard probability notation, derive the required expression from fundamental principles, and then compute the numerical value.\n\nLet $D$ be the event that the patient has sporotrichosis.\nLet $D^c$ be the event that the patient does not have sporotrichosis.\nLet $T^+$ be the event that the polymerase chain reaction (PCR) assay result is positive.\nLet $T^-$ be the event that the PCR assay result is negative.\n\nFrom the problem statement, we are given the following probabilities:\nThe pretest probability of sporotrichosis is the prior probability of the disease, $P(D)$.\n$$P(D) = 0.20$$\nThe sensitivity of the PCR assay is the probability of a positive test result given that the patient has the disease, $P(T^+ | D)$.\n$$P(T^+ | D) = 0.90$$\nThe specificity of the PCR assay is the probability of a negative test result given that the patient does not have the disease, $P(T^- | D^c)$.\n$$P(T^- | D^c) = 0.98$$\n\nOur objective is to derive an expression for and compute the numerical value of the post-test probability of sporotrichosis given a positive PCR result. This corresponds to the conditional probability $P(D | T^+)$.\n\nBy the definition of conditional probability, we have:\n$$P(D | T^+) = \\frac{P(D \\cap T^+)}{P(T^+)}$$\n\nThe numerator, $P(D \\cap T^+)$, is the joint probability of having the disease and testing positive. It can be expressed using the definition of conditional probability as:\n$$P(D \\cap T^+) = P(T^+ | D) P(D)$$\nThis expression contains two of our given values: the sensitivity and the pretest probability.\n\nThe denominator, $P(T^+)$, is the total probability of obtaining a positive test result. We can expand this term using the law of total probability, by conditioning on whether the patient has the disease ($D$) or not ($D^c$). These two events form a partition of the sample space.\n$$P(T^+) = P(T^+ \\cap D) + P(T^+ \\cap D^c)$$\nUsing the definition of conditional probability for each term, we get:\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\n\nThis expansion introduces two new terms we need to determine: $P(D^c)$ and $P(T^+ | D^c)$.\nThe probability of not having the disease, $P(D^c)$, is the complement of having the disease, $P(D)$:\n$$P(D^c) = 1 - P(D) = 1 - 0.20 = 0.80$$\nThe term $P(T^+ | D^c)$ is the probability of a positive test result given that the patient does not have the disease. This is the false positive rate. It is the complement of the specificity, $P(T^- | D^c)$, since for a patient without the disease, the test can only be positive or negative.\n$$P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - 0.98 = 0.02$$\n\nNow we substitute the expanded expressions for the numerator and the denominator back into our original formula for $P(D | T^+)$.\n$$P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)}$$\nThis is the final derived expression for the post-test probability, which is a form of Bayes' theorem. This expression is also known as the Positive Predictive Value (PPV) of the test.\n\nWe can now substitute the numerical values into this expression:\n$$P(D | T^+) = \\frac{(0.90)(0.20)}{(0.90)(0.20) + (0.02)(0.80)}$$\nFirst, we calculate the numerator and the individual terms in the denominator:\nNumerator: $0.90 \\times 0.20 = 0.18$\nDenominator, first term: $0.90 \\times 0.20 = 0.18$\nDenominator, second term: $0.02 \\times 0.80 = 0.016$\nSo, the expression becomes:\n$$P(D | T^+) = \\frac{0.18}{0.18 + 0.016} = \\frac{0.18}{0.196}$$\nNow, we perform the final division:\n$$P(D | T^+) = \\frac{0.18}{0.196} \\approx 0.9183673469...$$\nThe problem requires the answer to be rounded to four significant figures.\n$$P(D | T^+) \\approx 0.9184$$\n\nFor the clinical interpretation: The initial clinical suspicion (pretest probability) placed the patient's likelihood of having sporotrichosis at $20\\%$. After receiving a positive result from a highly specific PCR assay, the revised probability (post-test probability) has risen dramatically to approximately $92\\%$. A post-test probability of this magnitude is very high and strongly supports the diagnosis. In a clinical setting, this result would provide a high degree of confidence for the clinician to confirm sporotrichosis and initiate appropriate antifungal therapy, likely without the need for more invasive or time-consuming diagnostic procedures like tissue culture, which might otherwise be considered. The high specificity of the test ($98\\%$) means that false positives are rare, reinforcing the confidence in a positive result.",
            "answer": "$$\n\\boxed{0.9184}\n$$"
        },
        {
            "introduction": "While molecular tests are powerful, histopathologic examination remains crucial for a definitive diagnosis of sporotrichosis, but it is not without its challenges. This problem tests your ability to navigate common diagnostic pitfalls, from misinterpreting characteristic but nonspecific features to understanding the limitations of special stains . Recognizing these potential errors is a key skill for any pathologist or clinician relying on biopsy results.",
            "id": "4492693",
            "problem": "A $42$-year-old gardener presents with subcutaneous nodules arranged along lymphatic channels on the forearm and a proximal ulcer with purulent crust. A punch biopsy from the edge of a nodule demonstrates necrotizing granulomatous inflammation composed of epithelioid histiocytes and multinucleated giant cells. On hematoxylin and eosin examination, several eosinophilic star-like structures with radiating fibrils are noted in the necrotic center. Special stains are ordered. Grocott Methenamine Silver (GMS) is negative on the first pass, and Periodic Acid–Schiff (PAS) shows rare magenta, elongated “cigar-shaped” structures within histiocytes. The clinician queries the pathologist about diagnostic confidence for sporotrichosis and the risk of misdiagnosis.\n\nFrom the following, select all statements that describe histopathologic pitfalls relevant to tissue diagnosis of sporotrichosis.\n\nA. Treating eosinophilic “asteroid bodies” with radiate, Splendore-Hoeppli-type material as pathognomonic for Sporothrix schenckii complex, thereby bypassing mycologic confirmation.\n\nB. Interpreting a negative Grocott Methenamine Silver stain in a necrotizing granuloma as ruling out sporotrichosis, without considering the low organism burden and predominantly intracellular location of small yeasts.\n\nC. Mistaking elongated, cigar-shaped yeasts of approximately $2$–$6 \\,\\mu\\mathrm{m}$ within histiocytes for degenerated elastic fibers or collagen, resulting in underrecognition on routine hematoxylin and eosin sections.\n\nD. Assuming that mucicarmine-positive capsular staining supports sporotrichosis, rather than prompting consideration of Cryptococcus species and other encapsulated organisms.\n\nE. Using Fite-Faraco acid-fast positivity as confirmatory evidence for sporotrichosis in granulomatous inflammation, instead of raising concern for weakly acid-fast organisms such as Nocardia or Mycobacterium leprae.\n\nF. Recognizing that asteroid bodies are nonspecific immune complex deposits and, in the setting of sparse tissue yeasts, correlating with GMS/PAS, culture, and polymerase chain reaction (PCR) before rendering a specific fungal diagnosis.",
            "solution": "The problem statement describes a clinical and histopathological scenario highly suggestive of sporotrichosis and asks to identify common diagnostic pitfalls.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- **Patient Profile**: A $42$-year-old gardener.\n- **Clinical Findings**: Subcutaneous nodules arranged along lymphatic channels on the forearm; a proximal ulcer with purulent crust.\n- **Biopsy Findings (H&E)**: Necrotizing granulomatous inflammation with epithelioid histiocytes and multinucleated giant cells. Eosinophilic star-like structures (asteroid bodies) noted in the necrotic center.\n- **Special Stain Results**: Grocott Methenamine Silver (GMS) is negative on the first pass. Periodic Acid–Schiff (PAS) shows rare magenta, elongated “cigar-shaped” structures within histiocytes.\n- **Query**: The clinician is asking about diagnostic confidence for sporotrichosis and the risk of misdiagnosis.\n- **Task**: Identify statements describing histopathologic pitfalls relevant to the tissue diagnosis of sporotrichosis.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, and objective.\n- **Scientific Soundness**: The clinical presentation of a gardener with lymphocutaneous spread is a classic history for sporotrichosis. The histopathologic findings, including necrotizing granulomas, asteroid bodies, and the presence of rare, cigar-shaped yeasts on PAS stain, are all well-documented features of infection by the *Sporothrix schenckii* complex. The use and interpretation of special stains like GMS and PAS are standard practice in mycopathology. The problem is factually and scientifically sound.\n- **Well-Posedness**: The question asks to evaluate a series of statements regarding potential diagnostic errors (pitfalls) in this context. This is a clear and answerable question based on established principles of diagnostic pathology.\n- **Objectivity**: The description is clinical and factual, devoid of subjective or ambiguous language.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. It presents a realistic diagnostic challenge and asks for an evaluation of common errors in reasoning and interpretation within this context. The solution process will proceed.\n\n### Derivation and Option Analysis\n\nThe basis of this problem is the accurate histopathologic diagnosis of sporotrichosis, which can be challenging due to the paucibacillary nature of the infection and the non-specific nature of some histologic features. A pitfall is a potential error in diagnostic reasoning or interpretation. Each option will be evaluated to determine if it describes such a pitfall.\n\n**A. Treating eosinophilic “asteroid bodies” with radiate, Splendore-Hoeppli-type material as pathognomonic for Sporothrix schenckii complex, thereby bypassing mycologic confirmation.**\nThe Splendore-Hoeppli phenomenon, which results in the formation of asteroid bodies, is an immunological reaction where antigen-antibody complexes precipitate around a central microorganism or foreign body. While highly characteristic of sporotrichosis, these structures are not pathognomonic. They can be found in other fungal infections (e.g., candidiasis, blastomycosis), bacterial infections (e.g., nocardiosis, actinomycosis), parasitic infestations (e.g., schistosomiasis), and even in response to inert foreign material. Therefore, considering asteroid bodies as definitive proof of sporotrichosis without seeking confirmatory evidence (e.g., visualizing the organism with special stains, culture) is a significant diagnostic pitfall that could lead to misdiagnosis.\n**Verdict: Correct.** This statement accurately describes a major pitfall.\n\n**B. Interpreting a negative Grocott Methenamine Silver stain in a necrotizing granuloma as ruling out sporotrichosis, without considering the low organism burden and predominantly intracellular location of small yeasts.**\nCutaneous sporotrichosis is frequently a paucibacillary infection, meaning the density of fungal organisms in the tissue is very low. Consequently, a small biopsy sample may not contain any organisms, or they may be so sparse that they are missed on a single stained section. GMS stain, while generally excellent for fungi, can be negative in such cases. The case description itself presents this exact scenario. To rule out an infectious etiology based on a single negative stain, especially when the clinical and histologic patterns are highly suggestive, is a critical error. Multiple sections and other stains (like PAS, which was positive in this case) should be examined.\n**Verdict: Correct.** This statement correctly identifies a common pitfall related to the paucibacillary nature of the disease.\n\n**C. Mistaking elongated, cigar-shaped yeasts of approximately $2$–$6 \\,\\mu\\mathrm{m}$ within histiocytes for degenerated elastic fibers or collagen, resulting in underrecognition on routine hematoxylin and eosin sections.**\nThe characteristic \"cigar-shaped\" yeast forms of *Sporothrix* can be exceedingly difficult to identify on standard hematoxylin and eosin (H&E) stained sections. They are small (approximately $2$–$6 \\,\\mu\\mathrm{m}$ in length), often sparse, and can have pale, indistinct staining. They can be easily confused with cellular debris, nuclear fragments (\"smudge\"), or degenerated connective tissue elements within a dense inflammatory infiltrate or necrotic background. This mimicry leads to underrecognition of the causative agent on H&E alone, which is a significant diagnostic pitfall. Special stains like PAS or GMS are essential to highlight these forms.\n**Verdict: Correct.** This statement accurately describes a pitfall related to the subtle morphologic appearance of the organism on H&E.\n\n**D. Assuming that mucicarmine-positive capsular staining supports sporotrichosis, rather than prompting consideration of Cryptococcus species and other encapsulated organisms.**\nThe mucicarmine stain is used to detect acidic mucopolysaccharides. Its primary use in mycopathology is to highlight the thick polysaccharide capsule of *Cryptococcus* species, which stains a brilliant pink-red. *Sporothrix schenckii* does not possess a capsule that stains with mucicarmine. Therefore, a positive mucicarmine stain in a yeast-like organism within a granuloma would be strong evidence *against* sporotrichosis and should immediately raise suspicion for cryptococcosis. Assuming that a positive mucicarmine stain supports a diagnosis of sporotrichosis is a fundamental misinterpretation of the stain’s utility and constitutes a major diagnostic blunder.\n**Verdict: Correct.** This statement correctly identifies a pitfall involving the misinterpretation of a special stain.\n\n**E. Using Fite-Faraco acid-fast positivity as confirmatory evidence for sporotrichosis in granulomatous inflammation, instead of raising concern for weakly acid-fast organisms such as Nocardia or Mycobacterium leprae.**\nAcid-fast stains, such as the Fite-Faraco method, are designed to identify organisms that have a high lipid (mycolic acid) content in their cell walls, primarily mycobacteria and *Nocardia* species. Fungi, including *Sporothrix schenckii*, are not acid-fast and will be negative with these stains. A positive Fite-Faraco stain in a granulomatous lesion would point towards etiologies like leprosy (*Mycobacterium leprae*) or nocardiosis, both of which can be in the clinical and histologic differential diagnosis of sporotrichosis. Relying on acid-fast positivity to confirm sporotrichosis would be a gross error based on a misunderstanding of microbiology and staining principles.\n**Verdict: Correct.** This statement correctly identifies a pitfall involving the misinterpretation of another key special stain.\n\n**F. Recognizing that asteroid bodies are nonspecific immune complex deposits and, in the setting of sparse tissue yeasts, correlating with GMS/PAS, culture, and polymerase chain reaction (PCR) before rendering a specific fungal diagnosis.**\nThis statement describes the *correct* and prudent diagnostic algorithm. It involves recognizing the limitations of a non-specific finding (asteroid bodies), acknowledging the difficulty of finding sparse organisms, and appropriately using ancillary studies (special stains, culture, PCR) to arrive at a definitive diagnosis. This is the pathway to *avoiding* pitfalls. The question asks for statements that *describe pitfalls*. Therefore, this statement, which describes best practices, is not a pitfall.\n**Verdict: Incorrect.** This statement describes correct diagnostic procedure, not a pitfall.",
            "answer": "$$\\boxed{ABCDE}$$"
        },
        {
            "introduction": "With a confirmed diagnosis, the next step is designing a safe and effective treatment plan. This problem focuses on the pharmacokinetics of itraconazole, a cornerstone of therapy, challenging you to apply first principles to calculate an appropriate loading and maintenance dose . This practice reinforces the quantitative skills needed to optimize drug therapy and achieve rapid clinical response.",
            "id": "4492726",
            "problem": "A $70$ kg adult with lymphocutaneous sporotrichosis is initiated on itraconazole capsules. Assume a one-compartment, linear pharmacokinetic model with first-order elimination and that the following are known and applicable to itraconazole capsules under fed conditions: the apparent volume of distribution over bioavailability, denoted $V_d/F$, is $10\\,\\text{L/kg}$, and the apparent clearance over bioavailability, denoted $CL/F$, is $12\\,\\text{L/h}$. The dosing interval will be $\\tau = 24\\,\\text{h}$. The therapeutic target is an average steady-state plasma concentration $C_{\\text{ss,avg}} = 1\\,\\text{mg/L}$. Capsules are available in $100\\,\\text{mg}$ increments.\n\nUsing only the fundamental definitions of one-compartment linear pharmacokinetics (in particular, that the elimination rate constant is $k = (CL/F)/(V_d/F)$, the half-life is $t_{1/2} = \\ln(2)/k$, the average steady-state concentration under repeated dosing satisfies $C_{\\text{ss,avg}} = \\frac{(D/\\tau)}{(CL/F)}$ for dose $D$ given every $\\tau$, and the fraction of steady state achieved by time $t$ is $1 - \\exp(-kt)$), do the following:\n\n1) Derive the daily maintenance dose $D_{\\text{maint}}$ in $\\text{mg/day}$ that achieves $C_{\\text{ss,avg}}$, and round it to the nearest $100\\,\\text{mg}$ to match capsule strength, noting both the unrounded and rounded values.\n\n2) Derive an ideal oral loading dose $D_{\\text{load}}$ in $\\text{mg}$ that instantaneously achieves the target $C_{\\text{ss,avg}}$ at time $t=0$ in this model, and propose a division of $D_{\\text{load}}$ into two doses within the first $24$ hours consistent with $100\\,\\text{mg}$ capsule increments.\n\n3) Compute the elimination half-life $t_{1/2}$ in $\\text{hours}$ from the given parameters.\n\n4) Using the model’s approach to steady state, compute the time $t_{0.9}$ in $\\text{hours}$ to reach $0.9$ of steady state without a loading dose. Then, assuming an ideal loading dose is administered at $t=0$ that places the system on its steady-state concentration trajectory immediately, compute the time to reach $0.9$ of steady state with loading.\n\nFinally, report only the time saved by using the loading dose, defined as the difference in hours between the time to reach $0.9$ of steady state without loading and with loading. Express the final reported time in hours and round your answer to three significant figures.",
            "solution": "The problem statement is first validated to ensure it is scientifically sound, well-posed, and objective.\n\n**Step 1: Extract Givens**\nThe following data and definitions are provided in the problem statement:\n- Patient weight: $W = 70\\,\\text{kg}$\n- Apparent volume of distribution over bioavailability per kilogram: $(V_{d}/F)_{\\text{per kg}} = 10\\,\\text{L/kg}$\n- Apparent clearance over bioavailability: $(CL/F) = 12\\,\\text{L/h}$\n- Dosing interval: $\\tau = 24\\,\\text{h}$\n- Target average steady-state plasma concentration: $C_{\\text{ss,avg}} = 1\\,\\text{mg/L}$\n- Capsule strength is in increments of $100\\,\\text{mg}$.\n- The model is a one-compartment, linear pharmacokinetic model with first-order elimination.\n- The provided fundamental definitions are:\n  - Elimination rate constant: $k = (CL/F)/(V_{d}/F)$\n  - Half-life: $t_{1/2} = \\ln(2)/k$\n  - Average steady-state concentration: $C_{\\text{ss,avg}} = \\frac{(D/\\tau)}{(CL/F)}$\n  - Fraction of steady state achieved by time $t$: $1 - \\exp(-kt)$\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded (Critical)**: The problem is based on the standard one-compartment model, a cornerstone of pharmacokinetics. The use of itraconazole for lymphocutaneous sporotrichosis is a recognized medical therapy. The pharmacokinetic values provided are reasonable for itraconazole. The problem is scientifically sound.\n- **Well-Posed**: The problem is well-posed. It supplies all necessary parameters and equations to calculate the requested values. Each sub-question has a clear, unique solution derivable from the premises.\n- **Objective (Critical)**: The problem is stated using clear, precise, and unbiased language, employing standard-accepted terminology and definitions from the field of pharmacokinetics.\n- The problem is self-contained and consistent, with no missing information or contradictory constraints. It is not ill-posed, trivial, or reliant on pseudoscience.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\nThe solution proceeds by addressing each part of the problem in sequence. First, we must calculate the total apparent volume of distribution over bioavailability, $(V_d/F)_{\\text{total}}$, for the patient. The clearance, $(CL/F)$, is given as a total value and does not need to be scaled by weight.\nThe total apparent volume of distribution is:\n$$ (V_d/F)_{\\text{total}} = (V_d/F)_{\\text{per kg}} \\times W = (10\\,\\text{L/kg}) \\times (70\\,\\text{kg}) = 700\\,\\text{L} $$\n\n1) **Derivation of the daily maintenance dose, $D_{\\text{maint}}$**\nThe maintenance dose is determined using the given formula for the average steady-state concentration, $C_{\\text{ss,avg}}$.\n$$ C_{\\text{ss,avg}} = \\frac{D_{\\text{maint}}/\\tau}{(CL/F)} $$\nWe solve for the daily maintenance dose, $D_{\\text{maint}}$:\n$$ D_{\\text{maint}} = C_{\\text{ss,avg}} \\times (CL/F) \\times \\tau $$\nSubstituting the given values:\n$$ D_{\\text{maint}} = (1\\,\\text{mg/L}) \\times (12\\,\\text{L/h}) \\times (24\\,\\text{h}) = 288\\,\\text{mg} $$\nThis is the unrounded daily maintenance dose required to achieve the target average steady-state concentration. The problem states that capsules are available in $100\\,\\text{mg}$ increments. Rounding $288\\,\\text{mg}$ to the nearest $100\\,\\text{mg}$ gives a practical daily dose of $300\\,\\text{mg}$.\n\n2) **Derivation of the ideal oral loading dose, $D_{\\text{load}}$**\nAn ideal loading dose, $D_{\\text{load}}$, is designed to instantaneously achieve a target plasma concentration at time $t=0$. In a one-compartment model, the initial concentration $C_0$ is related to the dose $D$ by $C_0 = D \\times F / V_d$. Therefore, the dose required to achieve a target concentration $C_{\\text{target}}$ is $D = C_{\\text{target}} \\times V_d/F$. For the loading dose, the target concentration is the desired average steady-state concentration, $C_{\\text{ss,avg}}$.\n$$ D_{\\text{load}} = C_{\\text{ss,avg}} \\times (V_d/F)_{\\text{total}} $$\nSubstituting the values:\n$$ D_{\\text{load}} = (1\\,\\text{mg/L}) \\times (700\\,\\text{L}) = 700\\,\\text{mg} $$\nThis is the ideal loading dose. Since this is already a multiple of $100\\,\\text{mg}$, it is clinically achievable. A proposed division into two doses within the first $24$ hours could be, for example, $400\\,\\text{mg}$ administered at $t=0$ and $300\\,\\text{mg}$ administered $12$ hours later.\n\n3) **Computation of the elimination half-life, $t_{1/2}$**\nFirst, we compute the elimination rate constant, $k$, using the provided formula and the total pharmacokinetic parameters:\n$$ k = \\frac{(CL/F)}{(V_d/F)_{\\text{total}}} = \\frac{12\\,\\text{L/h}}{700\\,\\text{L}} = \\frac{12}{700}\\,\\text{h}^{-1} = \\frac{3}{175}\\,\\text{h}^{-1} $$\nNow, we compute the half-life, $t_{1/2}$:\n$$ t_{1/2} = \\frac{\\ln(2)}{k} = \\frac{\\ln(2)}{3/175}\\,\\text{h} = \\frac{175\\ln(2)}{3}\\,\\text{h} $$\nCalculation gives $t_{1/2} \\approx 40.43\\,\\text{h}$.\n\n4) **Computation of the time saved by using a loading dose**\nFirst, we find the time to reach $0.9$ (or $90\\%$) of steady state without a loading dose, denoted $t_{0.9}$. We use the given formula for the fraction of steady state, $f(t) = 1 - \\exp(-kt)$.\nLet $f(t_{0.9}) = 0.9$:\n$$ 0.9 = 1 - \\exp(-kt_{0.9}) $$\n$$ \\exp(-kt_{0.9}) = 1 - 0.9 = 0.1 $$\nTaking the natural logarithm of both sides:\n$$ -kt_{0.9} = \\ln(0.1) = -\\ln(10) $$\n$$ t_{0.9} = \\frac{\\ln(10)}{k} $$\nSubstituting the value of $k$:\n$$ t_{0.9} = \\frac{\\ln(10)}{3/175}\\,\\text{h} = \\frac{175\\ln(10)}{3}\\,\\text{h} $$\nNext, we consider the case with an ideal loading dose. The problem states that this dose \"places the system on its steady-state concentration trajectory immediately\". This is an idealization meaning the system behaves as if it is at steady state from $t=0$. Therefore, any fraction of steady state, including $0.9$, is achieved at $t=0$. The time to reach $0.9$ of steady state with a loading dose is $t_{0.9, \\text{load}} = 0\\,\\text{h}$.\n\nThe time saved by using the loading dose is the difference between the time to reach $0.9$ of steady state without the loading dose and with the loading dose.\n$$ \\text{Time saved} = t_{0.9} - t_{0.9, \\text{load}} = \\frac{175\\ln(10)}{3}\\,\\text{h} - 0\\,\\text{h} = \\frac{175\\ln(10)}{3}\\,\\text{h} $$\nTo provide the final answer, we compute the numerical value and round to three significant figures as requested.\n$$ \\text{Time saved} \\approx \\frac{175 \\times 2.302585}{3}\\,\\text{h} \\approx \\frac{402.9524}{3}\\,\\text{h} \\approx 134.3175\\,\\text{h} $$\nRounding to three significant figures, the time saved is $134\\,\\text{h}$.",
            "answer": "$$\n\\boxed{134}\n$$"
        }
    ]
}